LETTER TO THE EDITOR
The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha
Ezio Zanon,
Samantha Pasca,
Paolo Simioni,
Corresponding Author
Ezio Zanon
Hemophilia Center, University Hospital of Padua, Padova, Italy
Correspondence: Ezio Zanon, Hemophilia Center, University Hospital of Padua, Via Giustiniani - 35128 Padua, Italy ([email protected]).Search for more papers by this authorSamantha Pasca
Hemophilia Center, University Hospital of Padua, Padova, Italy
Search for more papers by this authorPaolo Simioni
Hemorrhagic and Thrombotic Diseases, University Hospital of Padua, Padova, Italy
Search for more papers by this authorEzio Zanon,
Samantha Pasca,
Paolo Simioni,
Corresponding Author
Ezio Zanon
Hemophilia Center, University Hospital of Padua, Padova, Italy
Correspondence: Ezio Zanon, Hemophilia Center, University Hospital of Padua, Via Giustiniani - 35128 Padua, Italy ([email protected]).Search for more papers by this authorSamantha Pasca
Hemophilia Center, University Hospital of Padua, Padova, Italy
Search for more papers by this authorPaolo Simioni
Hemorrhagic and Thrombotic Diseases, University Hospital of Padua, Padova, Italy
Search for more papers by this author
REFERENCES
- 1Franchini M, Santoro C, Coppola A. Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature review. Thromb Haemost. 2016; 116: 201-203.
- 2Di Michele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol. 2007; 138: 305-315.
- 3Soto I, Martinez D, Avila LF, Bernardo A. A rare case of late development of inhibitor in haemophilia B with a complex course, and review of literature. Haemophilia. 2018; 28: 1-4.
- 4Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant FIX Fc fusion protein in Hemophilia B. N Engl J Med. 2013; 369: 2313-2323.
- 5Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016; 127(14): 1761-1769.
- 6Carcao M, Zak M, Abdul Karim F, et al. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial. J Thromb Haemost. 2016; 14(8): 1521-1529.
- 7Castaman G, Bonetti E, Messina M, et al. Inhibitors in haemophilia B: the Italian experience. Haemophilia. 2013; 19(5): 686-690.
- 8Peyvandi F, Makris M, Collins P, et al. Minimal dataset for post-registration surveillance of need drugs in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2017; 15: 1878-1881.
- 9Iorio A, Barbara AM, Bernardi F, et al. Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2016; 14: 1668-1872.
- 10Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012; 10(6): 1055-1061.
- 11Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006; 12(Suppl 6): 5-22.
- 12Saini S, Hamasaki-Katagiri N, Pandey GS, et al. Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B. Haemophilia. 2015; 21(2): 210-218.
- 13Cugno M, Mancuso ME, Tedeschi A, et al. Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis. Haemophilia. 2017; 23(4): e348-e353.
Citing Literature
